AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27613125 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-mounted display self-learning
Number of subjects: 14
Study 26303336 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclidinium and formoterol
Number of subjects: 0
Study 26303336 — intervention group
Group type: COMPARATOR
Intervention: Aclidinium
Number of subjects: 0
Study 26303336 — intervention group
Group type: COMPARATOR
Intervention: Formoterol
Number of subjects: 0
Study 26303336 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclidinium plus formoterol
Number of subjects: 0
Study 23657857 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL) + L-NAME
Number of subjects: 23
Study 23657857 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo (PL) + L-NAME in DM
Number of subjects: 23
Study 23657857 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (LOS) pretreatment + L-NAME in DM
Number of subjects: 23
Study 20510977 — intervention group
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Number of subjects: 98
Study 20510977 — intervention group
Group type: COMPARATOR
Intervention: In-person assessments
Number of subjects: 98
Study 19192659 — intervention group
Group type: COMPARATOR
Intervention: 10,000 IU erythropoetin beta three times a week (group A)
Number of subjects: 119
Study 19192659 — intervention group
Group type: EXPERIMENTAL
Intervention: 20,000 IU erythropoetin beta twice a week (group B)
Number of subjects: 119
Study 16875904 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy with the ARB valsartan
Number of subjects: 350
Study 16875904 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 350
Study 12657339 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual counseling intervention (7 sessions over 9 months) based on PACE protocols
Number of subjects: 299
Study 12657339 — intervention group
Group type: COMPARATOR
Intervention: Control group (received written information about lifestyle factors)
Number of subjects: 299
Study 10638587 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (30 mg daily)
Number of subjects: 119
Study 10638587 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 119
Study 9365551 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 18000
Study 9365551 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18000
Study 1411317 — intervention group
Group type: EXPERIMENTAL
Intervention: Netilmicin
Number of subjects: 89
Study 1411317 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin
Number of subjects: 89
Study 1411317 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 89
Study 3516163 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine (500 mg daily)
Number of subjects: 38
Study 3516163 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 31667693 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterile carbon particle suspension (SCPS)
Number of subjects: 94
Study 31667693 — intervention group
Group type: COMPARATOR
Intervention: India ink
Number of subjects: 94
Study 31667693 — intervention group
Group type: EXPERIMENTAL
Intervention: SCPS
Number of subjects: 94
Study 28425497 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine 20 mg (p.o.)
Number of subjects: 18
Study 28425497 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 26072190 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed consent training
Number of subjects: 80
Study 23243228 — intervention group
Group type: EXPERIMENTAL
Intervention: Pleasant contact (PL) - chicks stroked gently for 30 s once daily from d 1 to 28
Number of subjects: 0
Study 23243228 — intervention group
Group type: EXPERIMENTAL
Intervention: Unpleasant contact (UNPL) - chicks suspended by legs and exposed to noise for 15 s once daily from d 1 to 28
Number of subjects: 0
Study 23243228 — intervention group
Group type: COMPARATOR
Intervention: Control - no physical or visual contact with humans
Number of subjects: 0
Study 23243228 — intervention group
Group type: EXPERIMENTAL
Intervention: PL-UNPL - chicks subjected to PL from d 1 to 14 and UNPL from d 15 to 28
Number of subjects: 0
Study 23243228 — intervention group
Group type: EXPERIMENTAL
Intervention: UNPL-PL - chicks subjected to UNPL from d 1 to 14 and PL from d 15 to 28
Number of subjects: 0
Study 23243228 — intervention group
Group type: EXPERIMENTAL
Intervention: PL and PL-UNPL treatments
Number of subjects: 0
Study 23243228 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum creatine kinase activity of PL
Number of subjects: 0
Study 21991728 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.25% and morphine 0.2 mg/mL
Number of subjects: 45
Study 21991728 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.25% and morphine 0.2 mg/mL and Xefocam 0.8 mg/mL
Number of subjects: 45
Study 21991728 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 45
Study 19960134 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic-based treatment (n=20)
Number of subjects: 38
Study 19960134 — intervention group
Group type: COMPARATOR
Intervention: Calcium channel blocker (CCB)-based treatment (n=18)
Number of subjects: 38
Study 16901484 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg/d) for >or=3 weeks
Number of subjects: 39
Study 14670569 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive battery including arithmetical tests (addition, subtraction, multiplication, division) and tests of understanding of numerosity and quantity (cognitive estimation, estimation, comparison, bisection, subitizing/counting)
Number of subjects: 25
Study 14670569 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (13 individuals)
Number of subjects: 25
Study 12383150 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 2581
Study 12383150 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate alcohol use
Number of subjects: 2581
Study 12383150 — intervention group
Group type: EXPERIMENTAL
Intervention: Selected medical conditions (diabetes mellitus, hypertension, coronary heart disease, cerebrovascular disease (CVD), osteoporosis, arthritis, and cancer)
Number of subjects: 2581
Study 12383150 — intervention group
Group type: EXPERIMENTAL
Intervention: Low cognitive function
Number of subjects: 2581
Study 12383150 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 2581
Study 12383150 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 2581
Study 12383150 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary heart disease
Number of subjects: 2581
Study 12383150 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrovascular disease (CVD)
Number of subjects: 2581
Study 12383150 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoporosis
Number of subjects: 2581
Study 12383150 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthritis
Number of subjects: 2581
Study 12383150 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer
Number of subjects: 2581
Study 9878104 — intervention group
Group type: EXPERIMENTAL
Intervention: Event-monitoring task
Number of subjects: 8
Study 9878104 — intervention group
Group type: EXPERIMENTAL
Intervention: Event-mapping task
Number of subjects: 8
Study 8031275 — intervention group
Group type: EXPERIMENTAL
Intervention: Affected eyes at baseline
Number of subjects: 448
Study 8031275 — intervention group
Group type: EXPERIMENTAL
Intervention: Affected eyes at 6 months
Number of subjects: 448
Study 8031275 — intervention group
Group type: EXPERIMENTAL
Intervention: Affected eyes at 1 year
Number of subjects: 448
Study 8031275 — intervention group
Group type: EXPERIMENTAL
Intervention: Fellow eyes at baseline
Number of subjects: 448
Study 8031275 — intervention group
Group type: EXPERIMENTAL
Intervention: Fellow eyes at 6 months
Number of subjects: 448
Study 8031275 — intervention group
Group type: EXPERIMENTAL
Intervention: Fellow eyes at 1 year
Number of subjects: 448
Study 8031275 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with retrochiasmal visual field defect
Number of subjects: 448
Study 8031275 — intervention group
Group type: COMPARATOR
Intervention: Other patients in the trial
Number of subjects: 448
Study 8031275 — intervention group
Group type: EXPERIMENTAL
Intervention: Binocular analysis
Number of subjects: 448
Study 3042576 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg q.i.d.)
Number of subjects: 56
Study 3042576 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (150 mg b.i.d. + placebo b.i.d.)
Number of subjects: 56
Study 31039386 — intervention group
Group type: EXPERIMENTAL
Intervention: 45S5 Bioglass
Number of subjects: 66
Study 31039386 — intervention group
Group type: COMPARATOR
Intervention: Fluoride 4-minutes
Number of subjects: 66
Study 31039386 — intervention group
Group type: COMPARATOR
Intervention: Fluoride 24-Hours
Number of subjects: 66
Study 31039386 — intervention group
Group type: COMPARATOR
Intervention: Temp (Caviton)
Number of subjects: 66
Study 28433923 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry juice
Number of subjects: 17
Study 28433923 — intervention group
Group type: COMPARATOR
Intervention: Apple juice
Number of subjects: 17
Study 24280956 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma rich in growth factors
Number of subjects: 0
Study 24280956 — intervention group
Group type: COMPARATOR
Intervention: Control group (no plasma rich in growth factors)
Number of subjects: 0
Study 23447607 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocks highly biased toward punishment
Number of subjects: 0
Study 23447607 — intervention group
Group type: EXPERIMENTAL
Intervention: DA antagonist administration
Number of subjects: 0
Study 23447607 — intervention group
Group type: COMPARATOR
Intervention: Predetermined maximal acceleration (MA) execution
Number of subjects: 0
Study 23447607 — intervention group
Group type: COMPARATOR
Intervention: Resting neurophysiological variability
Number of subjects: 0
Study 21303308 — intervention group
Group type: EXPERIMENTAL
Intervention: VX‐770
Number of subjects: 0
Study 19825284 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (intravenously once a day for 4 weeks, then orally once daily for another 4 weeks)
Number of subjects: 97
Study 19825284 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (intravenously once a day for 5 days)
Number of subjects: 97
Study 19825284 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard anti-tuberculosis drugs only)
Number of subjects: 97
Study 19825284 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (dexamethasone, methylprednisolone, control)
Number of subjects: 97
Study 16715530 — intervention group
Group type: EXPERIMENTAL
Intervention: NT measurement >or= 95th centile for crown‐rump length
Number of subjects: 16383
Study 16715530 — intervention group
Group type: EXPERIMENTAL
Intervention: NT measurement >or= 3.0 mm
Number of subjects: 16383
Study 16715530 — intervention group
Group type: EXPERIMENTAL
Intervention: NT measurement >or= 3.5 mm
Number of subjects: 16383
Study 14666387 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET
Number of subjects: 19
Study 14666387 — intervention group
Group type: EXPERIMENTAL
Intervention: (99m)Tc-MIBI SPET
Number of subjects: 19
Study 14666387 — intervention group
Group type: EXPERIMENTAL
Intervention: (131)I scintigraphy
Number of subjects: 19
Study 11766940 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimation of sizes of common objects from memory
Number of subjects: 0
Study 11766940 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimation of sizes and distances of objects displayed in front of subjects
Number of subjects: 0
Study 11766940 — intervention group
Group type: EXPERIMENTAL
Intervention: Good distance information
Number of subjects: 0
Study 11766940 — intervention group
Group type: EXPERIMENTAL
Intervention: Far distances
Number of subjects: 0
Study 9264417 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (8 mg cumulative dose or maximum heart rate reduction of 25%)
Number of subjects: 17
Study 9264417 — intervention group
Group type: COMPARATOR
Intervention: Control (dobutamine stress test without propranolol)
Number of subjects: 17
Study 8282676 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 41
Study 8282676 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 3234607 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback training
Number of subjects: 12
Study 3234607 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment alone
Number of subjects: 12
Study 29576125 — intervention group
Group type: EXPERIMENTAL
Intervention: PECs blocks (levobupivacaine 0.25%, 10 ml PECs I and 20 ml PECs II)
Number of subjects: 45
Study 29576125 — intervention group
Group type: EXPERIMENTAL
Intervention: LA infusion (levobupivacaine 0.1% at 10 ml h‐1 for 24 h)
Number of subjects: 45
Study 29576125 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PECs and LA infusion
Number of subjects: 45
Study 28410749 — intervention group
Group type: EXPERIMENTAL
Intervention: K-877 (pemafibrate) 0.1, 0.2, and 0.4 mg/day in combination with pitavastatin for 12 weeks
Number of subjects: 611
Study 28410749 — intervention group
Group type: EXPERIMENTAL
Intervention: K-877 (pemafibrate) 0.2 mg/day (fixed dose) and 0.2 (0.4) mg/day (conditional up-titration) in combination with any statin for 24 weeks
Number of subjects: 611
Study 28410749 — intervention group
Group type: EXPERIMENTAL
Intervention: K-877 add-on therapy
Number of subjects: 611
Study 28410749 — intervention group
Group type: COMPARATOR
Intervention: K-877 combination therapy
Number of subjects: 611
Study 25535783 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide for three hours a day for three weeks
Number of subjects: 60
Study 25535783 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonsmokers)
Number of subjects: 60
Study 22370870 — intervention group
Group type: EXPERIMENTAL
Intervention: Xiaopi-I
Number of subjects: 134
Study 22370870 — intervention group
Group type: COMPARATOR
Intervention: Domperidone
Number of subjects: 134
Study 20494730 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 microg misoprostol sublingually
Number of subjects: 1422
Study 20494730 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1422
Study 18179785 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine (50 mg)
Number of subjects: 56
Study 18179785 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 16942565 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with tree pollen extract, accumulated weekly dose of 200,000 SQ-U, 5 days a week for up to 18 months
Number of subjects: 88
Study 16942565 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with tree pollen extract, accumulated weekly dose of 24,000 SQ-U, 5 days a week for up to 18 months
Number of subjects: 88
Study 16942565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 15385016 — intervention group
Group type: EXPERIMENTAL
Intervention: remifentanil + propofol
Number of subjects: 20
Study 15385016 — intervention group
Group type: COMPARATOR
Intervention: propofol alone
Number of subjects: 20
Study 11421892 — intervention group
Group type: EXPERIMENTAL
Intervention: Health complications during pregnancy
Number of subjects: 4065
Study 11421892 — intervention group
Group type: EXPERIMENTAL
Intervention: Health complications during labor or delivery
Number of subjects: 4065
Study 11421892 — intervention group
Group type: EXPERIMENTAL
Intervention: Child illness or health complications during the first week of life
Number of subjects: 4065
Study 11421892 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth weight of < 2.5 kg
Number of subjects: 4065
Study 11421892 — intervention group
Group type: EXPERIMENTAL
Intervention: Early or threatened labor (ICD: 644)
Number of subjects: 4065
Study 11421892 — intervention group
Group type: EXPERIMENTAL
Intervention: Malposition or malpresentation of the fetus (ICD: 652)
Number of subjects: 4065
Study 9241010 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone 6 mg/day
Number of subjects: 135
Study 9241010 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 135
Study 9241010 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study 8390528 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 20 mg once a day
Number of subjects: 80
Study 8390528 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide 25 mg once a day
Number of subjects: 80
Study 2942164 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 2.5 mg
Number of subjects: 200
Study 2942164 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone 20 mg
Number of subjects: 200
Study 2942164 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg
Number of subjects: 200
Study 2942164 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 200
Study 31856984 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification combined with viscosynechialysis and trabeculotomy (phaco-viscosynechialysis group)
Number of subjects: 59
Study 31856984 — intervention group
Group type: COMPARATOR
Intervention: Phacoemulsification combined with trabeculectomy (phacotrabeculectomy group)
Number of subjects: 59
Study 28930850 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute normovolemic hemodilution (ANH) combined with intraoperative cell salvage (ICS)
Number of subjects: 80
Study 28930850 — intervention group
Group type: COMPARATOR
Intervention: Intraoperative cell salvage (ICS) alone (Control group)
Number of subjects: 80
Study 28930850 — intervention group
Group type: EXPERIMENTAL
Intervention: ANH
Number of subjects: 80
Study 28930850 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study 24983306 — intervention group
Group type: EXPERIMENTAL
Intervention: Valganciclovir or ganciclovir
Number of subjects: 291
Study 23418635 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete cochlear implantation (activation of all electrodes)
Number of subjects: 7
Study 23418635 — intervention group
Group type: COMPARATOR
Intervention: Activation of basal electrode pairs (E12) nearest to the round window
Number of subjects: 7
Study 23418635 — intervention group
Group type: COMPARATOR
Intervention: Non-implanted control group
Number of subjects: 7
Study 20847081 — intervention group
Group type: EXPERIMENTAL
Intervention: nCPAP
Number of subjects: 140
Study 20847081 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 140
Study 19294678 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral azithromycin, 500 mg per day for 3 days before amniocentesis
Number of subjects: 34923
Study 19294678 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antibiotic prophylaxis)
Number of subjects: 34923
Study 17378260 — intervention group
Group type: EXPERIMENTAL
Intervention: SLIT for grass
Number of subjects: 58
Study 17378260 — intervention group
Group type: EXPERIMENTAL
Intervention: SLIT for birch
Number of subjects: 58
Study 17378260 — intervention group
Group type: EXPERIMENTAL
Intervention: SLIT for birch and grass
Number of subjects: 58
Study 17378260 — intervention group
Group type: COMPARATOR
Intervention: Drugs only
Number of subjects: 58
Study 15100593 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (150 mg/day, titrated to 1200 mg/day)
Number of subjects: 30
Study 15100593 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (1200 mg/day during Maintenance Phase)
Number of subjects: 30
Study 11281158 — intervention group
Group type: EXPERIMENTAL
Intervention: hPTH plus hormone-replacement therapy (HRT)
Number of subjects: 15
Study 11281158 — intervention group
Group type: COMPARATOR
Intervention: HRT alone
Number of subjects: 15
Study 11281158 — intervention group
Group type: EXPERIMENTAL
Intervention: hPTH plus HRT
Number of subjects: 15
Study 9397118 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy (ERT) with 2 mg/day of oral micronized estradiol for 12 weeks
Number of subjects: 28
Study 8267176 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasmapheresis before cardiopulmonary bypass (CPB)
Number of subjects: 40
Study 8267176 — intervention group
Group type: COMPARATOR
Intervention: Normal management without pheresis (Control)
Number of subjects: 40
Study 3125546 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabexelate mesilate (FOY)
Number of subjects: 42
Study 3125546 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study 30943824 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth tool used by community health workers to calculate CVD risk and confirm physician appointments.
Number of subjects: 755
Study 30943824 — intervention group
Group type: COMPARATOR
Intervention: Paper-based tool used by community health workers for screening CVD risk.
Number of subjects: 755
Study 28840742 — intervention group
Group type: EXPERIMENTAL
Intervention: International Ballroom Dancing (IG) for 10 months
Number of subjects: 129
Study 28840742 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 129
Study 25540980 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein (HP) diet
Number of subjects: 932
Study 25540980 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycemic index (LGI) diet
Number of subjects: 932
Study 25540980 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of HP and LGI diets
Number of subjects: 932
Study 25540980 — intervention group
Group type: EXPERIMENTAL
Intervention: DioGenes diet
Number of subjects: 932
Study 25540980 — intervention group
Group type: EXPERIMENTAL
Intervention: HP effects after 1 year
Number of subjects: 932
Study 23561876 — intervention group
Group type: EXPERIMENTAL
Intervention: Core exercise group
Number of subjects: 40
Study 21642060 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand splint with reflex inhibitory characteristics (worn at least 2 hours each day)
Number of subjects: 19
Study 21642060 — intervention group
Group type: COMPARATOR
Intervention: Control group (no splint)
Number of subjects: 19
Study 21642060 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand splint with reflex inhibitory characteristics
Number of subjects: 19
Study 18626487 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical lidocaine jelly
Number of subjects: 25
Study 18626487 — intervention group
Group type: COMPARATOR
Intervention: Placebo jelly
Number of subjects: 25
Study 17040558 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI examination
Number of subjects: 0